WHITE MICHAEL ANTHONY 4

What Happened

• Michael Anthony White, Chief Scientific Officer of IDEAYA Biosciences (IDYA), was granted a derivative award covering 190,000 shares on January 30, 2026. The Form 4 reports an acquisition price of $0.00 per share (transaction code A — grant/award), so this was an equity award rather than an open-market purchase.

Key Details

• Transaction date: 2026-01-30 (reported on Form 4 filed 2026-02-02, accession 0001610717-26-000037)
• Amount: 190,000 shares reported as a derivative award at $0.00 per share
• Shares owned after transaction: Not disclosed in the provided data
• Footnote (vesting): 25% vests on the first anniversary measured from Jan 1, 2026 (the Vesting Commencement Date); thereafter 1/48th of the total vests monthly so the award becomes 100% vested on the fourth anniversary of the Vesting Commencement Date
• Timeliness: Form 4 filed shortly after the grant date (no late-filing flag provided)

Context

• This is a compensation-related equity award (not a market purchase or sale). Such grants are common for executives and are meant to align incentives; they do not by themselves indicate that the insider bought or sold stock in the open market.
• The award is reported as a derivative security. There is no indication here of an immediate exercise or sale (no cashless exercise or disposition reported).